

# Houston Hosts New MS Study

*Groundbreaking Study Seeks Participants*

HOUSTON, TEXAS, USA, March 28, 2024 /EINPresswire.com/ -- Clinical Trial Network of Texas is accepting participants in a new study on [Multiple Sclerosis \(MS\)](#).

MS is a chronic autoimmune disorder affecting the central nervous system. The immune system begins to erroneously attack the myelin sheath protecting the nerve fibers, damaging the lines of communication between the brain and the body.

MS symptoms include numbness or weakness in one or more limbs, tingling sensations, coordination problems, difficulty walking, partial or complete vision loss, vertigo, sexual dysfunction, bowel dysfunctions, bladder dysfunctions, fatigue, slurred speech, cognitive challenges, and mood disturbances. These symptoms can be debilitating. Many people with MS struggle with mobility and daily functioning.

“

Clinical trials are a critical tool for improving our understanding of how to treat and manage diseases like MS”


*Alejandra Meza*

Nearly 1 million people in the U.S. live with MS. There are four types of MS.

This study will focus on Relapsing-Remitting (MS), or RRMS. RRMS covers 85% of diagnoses and is characterized by episodes of new symptoms followed by periods of remission. The study will test a new therapy designed to help MS participants manage the condition. Skilled

research coordinators and clinicians will conduct the 34-week study.

"Clinical trials are a critical tool for improving our understanding of how to treat and manage diseases like MS," notes Alejandra Meza, a Patient Enrollment Specialist at Clinical Trial Network



Discover Hope:  
**Seeking Participants for Clinical Studies for Multiple Sclerosis (MS)**

Are you interested in advancing MS research and exploring new treatment options?

See if you Qualify

of Texas.

Potential participants qualify for the study if they are between the ages of 18 and 50 and have been diagnosed with Relapsing MS within the last ten years. Participants must currently be on no more than one immunomodulatory medication.

Study participants will be compensated up to \$50 per visit or up to \$300 upon completion. Transportation is provided for seven visits, which covers all the trips required by the study. Study participants do not need insurance to participate.

In addition to compensation and the opportunity to potentially try groundbreaking treatments, participants will contribute to the medical industry's ability to better understand MS. The information provided by this study will advance MS research and may expand MS treatment options. There is no guarantee that study participants will benefit directly from the study, and side effects are possible.

Clinical Trial Network is now accepting applications. For more information, visit: <https://www.clinicalstudieshouston.com/multiple-sclerosis-study/>

## CONTACT

Alejandra Meza  
Patient Enrollment Specialist  
713-322-8430

## ABOUT CLINICAL TRIAL NETWORK

Clinical Trial Network conducts clinical trials in multiple specialty areas. It is known for being a reliable and dedicated research facility offering several study options to Houston-area volunteers. The network is devoted to collecting accurate data and routinely produces industry-grade Ph I-IV clinical trials. It is headquartered in Houston, TX.

Alejandra Meza  
Clinical Trial Network



Discover Hope:  
**Understanding and Managing Multiple Sclerosis (MS)**

Are you interested in advancing MS research and exploring new treatment options?  
Consider joining a clinical study:

- Ages 18-50
- Diagnosed with Relapsing MS within the last 10 years
- Currently on no or no more than one immunomodulatory medication

[Request More Information](#)

713-322-8430

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/698995437>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.